WO2019245513A2 - A combination comprising fingolimod and amantadine - Google Patents
A combination comprising fingolimod and amantadine Download PDFInfo
- Publication number
- WO2019245513A2 WO2019245513A2 PCT/TR2019/050477 TR2019050477W WO2019245513A2 WO 2019245513 A2 WO2019245513 A2 WO 2019245513A2 TR 2019050477 W TR2019050477 W TR 2019050477W WO 2019245513 A2 WO2019245513 A2 WO 2019245513A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablets
- pharmaceutical combination
- combination according
- fingolimod
- amantadine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Definitions
- the present invention relates to a pharmaceutical combination comprising fingolimod or a pharmaceutically acceptable salt thereof and amantadine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple sclerosis in human, preferably in the prevention or the treatment of fatigue symptom of multiple sclerosis disease.
- MS Multiple Sclerosis
- CNS central nervous system
- Myelin provides a covering or insulation for nerves, improves the conduction of impulses along the nerves and also is important for maintaining the health of the nerves.
- inflammation causes the myelin to disappear. So, the electrical impulses become slower.
- the nerves themselves are damaged. Patient suffers from a range of symptoms which affect their health-related quality of life such as pain, fatigue, muscle spasticity and spasm, bladder problems and sleep disturbance.
- Fingolimod is a sphingosine-1 -phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Fingolimod is used in the treatment of the relapsing form of multiple sclerosis. May also be used in chronic inflammatory demyelinating polyneuropathy.
- Fingolimod is marketed by Novartis under the brand name Gilenya® for the treatment of multiple sclerosis.
- Gilenya® is presented as immediate-release hard gelatin capsules containing 0.56 mg of fingolimod hydrochloride as the active substance corresponding to 0.5 mg of fingolimod.
- fingolimod 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1 ,3-diol. Fingolimod is shown as Formula I.
- fingolimod derivatives are firstly disclosed in US5604229.
- the use of fingolimod derivatives as immune depressant and preventive for autoimmune diseases is disclosed in EP0627406 (B1).
- the use of fingolimod derivatives in the prevention or in the treatment of chronic rejection in a recipient of organ or tissue alio- or xeno-transplant is disclosed in EP0941082 (B1).
- MS fatigue is a common symptom of people with MS. This is called “MS fatigue” and this is different from fatigue experienced by persons without MS. This also can arise from associated conditions or accumulation of disease burden. Specific causes to consider include sleep disorders, depression, disability status.
- Multiple sclerosis is a heterogeneous disease that develops as an interplay between the immune system and environmental stimuli in genetically susceptible individuals.
- viruses may play a role in MS pathogenesis acting as these environmental triggers.
- CNS & Neurological Disorders - Drug Targets 2012 Aug, Viruses and Multiple Sclerosis, Jussi Oskari Virtanen, Steve Jacobson.
- antiviral agents amantadine, rimantadine, zanamivir, oseltamivir, peramivir.
- Amantadine is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia.
- the chemical name of amantadine is 1-adamantanamine. Its molecular weight is 151.253 with a molecular formula C H N. It has the following structural formula as Formula II.
- fingolimod with amantadine in the prior art.
- combining more than one molecule in one dosage form increases the patient’s compliance.
- combining more than one molecule in one dosage form also reduces undesired multiple sclerosis symptoms and provide effective treatment.
- the main object of the present invention is to combine fingolimod with amantadine to eliminate multiple sclerosis symptoms and to provide effective treatment.
- Another object of the present invention is to obtain a stable combination formulation with a synergistic effect for use in multiple sclerosis.
- This invention also provides a pharmaceutical combination comprising effective amount of fingolimod and an effective amount of amantadine, for use in treating a human afflicted with multiple sclerosis.
- the combination is administered simultaneously, separately or sequentially.
- fingolimod refers to fingolimod in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof.
- amantadine refers to amantadine in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof.
- the pharmaceutical combination comprises fingolimod and amantadine.
- the combination is used as adjunctive therapy in fatigue for multiple sclerosis treatment.
- the combination is for use in the treatment of multiple sclerosis in human.
- the combination is for use to prevent or treatment fatigue symptom of MS disease.
- An embodiment of this present invention is to combine fingolimod with amantadine in a same and stable dosage form with desired dissolution profiles.
- This invention provides a method of treating a human afflicted with multiple sclerosis comprising periodical administration of an amount of fingolimod and amantadine to the subject together, wherein these amounts described below are effective to treat a human.
- the pharmaceutical combination comprises fingolimod is present in an amount of between 0.05 and 20 mg and amantadine is present in an amount of between 50 and 200 mg.
- the weight ratio of fingolimod to amantadine is between 0.0001 - 2.0, preferably 0.001 - 1.0 or more preferably 0.002 - 0.4.
- said combination further comprises at least one pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, solvents and co-solvents, rate controlling polymers, direct compression agent, surfactants, lubricants, glidants, sweeteners, stabilizers, coating agents, coloring agents or inert agents or mixtures thereof.
- at least one pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, solvents and co-solvents, rate controlling polymers, direct compression agent, surfactants, lubricants, glidants, sweeteners, stabilizers, coating agents, coloring agents or inert agents or mixtures thereof.
- Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
- Suitable binders are selected from the group comprising polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponite, bentonite, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
- Suitable disintegrants are selected from the group comprising polyvinyl pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
- polyvinyl pyrrolidone crospovidone
- povidone povidone
- carboxymethyl cellulose croscarmellose sodium
- low-substituted hydroxypropyl cellulose pregelatinized
- Suitable solvents or co-solvents are selected from the group comprising water, propylene glycol, glycerin, ethanol, polyethylene glycol or mixtures thereof.
- Suitable rate controlling polymers are selected from the group comprising ethyl acrylate, ethyl methacrylate copolymer, ethylcellulose, methylcellulose, hypromellose phthalate, polydextrose, polyvinylacetate phthalate, zein, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, , hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, acacia, dextrin, starch, polyhydroxyethylmethacrylate, sodium carboxymethylcellulose, carboxymethyl cellulose, sodium alginate, alginic acid, pectin, polyglucoronic acid, polygalacturonic acid, chondroitic sulfate, carrageenan, lambda carregeenan, iota carregeenan, furcellaran, xanthan gum, a polymer
- Suitable direct compression agents are selected from the group comprising calcium hydrogen phosphate sodium alginate, pregelatinized starch, calcium citrate or mixtures thereof.
- Suitable surfactants are selected from the group comprising sodium docusate, glyceryl monooleate, polyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, sorbic acid, sorbitan fatty acid ester, nonoxynol, polyoxyethylene stearates, polyethylene glycol, leucine, poloxamer 407, sodium benzoate, docusate sodium, alpha tocopherol, ascorbyl palmitate, citric acid, polyethoxylated fatty acid esters, polyoxyethylene hydrogenated castor oil or mixtures thereof.
- Suitable lubricants are selected from the group comprising from magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
- Suitable glidants are selected from the group comprising colloidal silicon dioxide, corn starch, talc or mixtures thereof.
- Suitable sweeteners are selected from the group comprising aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose or sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
- Suitable stabilizers are selected from the group comprising citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglumine, ascorbic acid, gallic acid esters or the mixtures thereof, and preferably, citric acid, fumaric acid, arginine or mixtures thereof.
- Suitable coating agent are selected from the group comprising polymethacrylates, polyalkylacrylates copolymers, hydroxyl propyl methyl cellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol- polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
- Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
- FD&C Food, Drug & Cosmetic
- Suitable inert agents between the two molecules are selected from starch, lactose, sugar alcohol like D-mannitol, erythritol; low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, hydroxyethyl methylcellulose or mixtures thereof.
- the pharmaceutical combination is administered orally.
- the pharmaceutical combination is in the form of tablets, capsules, strips, syrups, powders, pastilles, sachets, effervescent compositions, pills, coated bead systems, granules, microspheres, dragees, films, orally administrable films, solutions, solids, suspensions or emulsions.
- the pharmaceutical combination is in the form of tablets or capsules.
- the pharmaceutical combination is in the form of a tablet.
- the pharmaceutical combination is formulated as tablets comprising film- coated tablets, bilayer tablets, trilayer tablets, inlay tablets, orally disintegrating tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, buccal tablets, sublingual tablets, effervescent tablets, gastric disintegrating tablets, chewable tablets, dispersing tablets or lozenges.
- the pharmaceutical combination is in the form of a film-coated tablet or bilayer tablet or trilayer tablet.
- the pharmaceutical combination is in the form of a capsule.
- the combination is prepared using direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion, spheronization, slugging, spray drying or solvent evaporation.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19823241.5A EP3810110A4 (en) | 2018-06-21 | 2019-06-20 | A combination comprising fingolimod and amantadine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201808819 | 2018-06-21 | ||
TR2018/08819 | 2018-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019245513A2 true WO2019245513A2 (en) | 2019-12-26 |
WO2019245513A3 WO2019245513A3 (en) | 2020-03-19 |
Family
ID=68983747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2019/050477 WO2019245513A2 (en) | 2018-06-21 | 2019-06-20 | A combination comprising fingolimod and amantadine |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3810110A4 (en) |
WO (1) | WO2019245513A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016073510A1 (en) | 2014-11-04 | 2016-05-12 | Adamas Pharmaceuticals, Inc. | Methods of administering amantadine compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
WO2016064997A1 (en) * | 2014-10-22 | 2016-04-28 | The Regents Of The University Of California | Compositions and methods for treating fatigue and depression |
-
2019
- 2019-06-20 WO PCT/TR2019/050477 patent/WO2019245513A2/en active Application Filing
- 2019-06-20 EP EP19823241.5A patent/EP3810110A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016073510A1 (en) | 2014-11-04 | 2016-05-12 | Adamas Pharmaceuticals, Inc. | Methods of administering amantadine compositions |
Also Published As
Publication number | Publication date |
---|---|
EP3810110A4 (en) | 2022-03-16 |
WO2019245513A3 (en) | 2020-03-19 |
EP3810110A2 (en) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784819C (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
AU2017300185B2 (en) | Extended release dosage forms of pregabalin | |
US20080069873A1 (en) | Controlled release system and method for manufacturing the same | |
JP2018500353A (en) | Ileum-jejunum drug delivery composition | |
US8802143B2 (en) | Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs | |
EP3723755A2 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
US20180000792A1 (en) | Modified release compositions of epalrestat or a derivative thereof and methods for using the same | |
EP3893866A2 (en) | A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent | |
KR20140140353A (en) | Oral combined formulation with improved stability and compatibility | |
WO2019245513A2 (en) | A combination comprising fingolimod and amantadine | |
WO2020117151A2 (en) | A combination comprising fingolimod and modafinil | |
EP2391353A1 (en) | Pharmaceutical compositions of trimetazidine | |
WO2009019662A2 (en) | Oral metaxalone compositions | |
EP3810274A2 (en) | A combination comprising fingolimod and at least one anti-epileptic agent | |
US20200338025A1 (en) | Extended release midodrine hydrochloride compositions and methods of use | |
EP3890720A1 (en) | A combination comprising dimethyl fumarate and at least one muscle relaxant agent | |
EP3893855A2 (en) | A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent | |
US20160143923A1 (en) | Low dose pharmaceutical composition of doxycycline | |
TR2022010905A2 (en) | A COMBINATION CONTAINING FAMPYRIDINE AND A CORTICOSTEROID AGENT | |
WO2012129759A1 (en) | Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
EP3902531A2 (en) | Pharmaceutical combinations comprising fingolimod and a spasmolytic | |
US20170189374A1 (en) | Zaltoprofen and muscle relaxant combinations | |
TR2021021540A2 (en) | A COMBINATION COMPRISING IBUPROFEN AND AT LEAST ONE ATYPICAL ANTIPSYCHOTIC AGENT | |
EP2801352A1 (en) | Orally disintegrating formulations of Lacosamid | |
WO2019203748A2 (en) | The composition comprising raloxifene with at least one antipsychotic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19823241 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019823241 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019823241 Country of ref document: EP Effective date: 20210121 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19823241 Country of ref document: EP Kind code of ref document: A2 |